Fennec Pharmaceuticals (STU:RV41) Long-Term Capital Lease Obligation : €0.00 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Fennec Pharmaceuticals Long-Term Capital Lease Obligation?

Fennec Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil.

Fennec Pharmaceuticals's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€0.01 Mil) to Dec. 2023 (€0.00 Mil) and declined from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€0.00 Mil).

Fennec Pharmaceuticals's annual Long-Term Capital Lease Obligation stayed the same from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Fennec Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Fennec Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Long-Term Capital Lease Obligation Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

Fennec Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	0.01	-	-

Fennec Pharmaceuticals (STU:RV41) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Fennec Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (STU:RV41) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

FENC:USA FRX:Canada

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals (STU:RV41) Headlines

No Headlines